2022-12-202022-12-202022-08-24Jatuworapruk, K., Montgomery, A., Gianfrancesco, M., Conway, R., Durcan, L., Graef, E.R., Jayatilleke, A., Keen, H., Kilian, A., Young, K., Carmona, L., Cogo, A.K., Duarte-García, A., Gossec, L., Hasseli, R., Hyrich, K.L., Langlois, V., Lawson-Tovey, S., Malcata, A., Mateus, E.F., Schafer, M., Scirè, C.A., Sigurdardottir, V., Sparks, J.A., Strangfeld, A., Xavier, R.M., Bhana, S., Gore-Massy, M., Hausmann, J., Liew, J.W., Sirotich, E., Sufka, P., Wallace, Z., Machado, P.M., Yazdany, J., Grainger, R. and Robinson, P.C. (2022), Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. ACR Open Rheumatology, 4: 948-953. https://doi.org/10.1002/acr2.114952578-5745http://dx.doi.org/10.34944/dspace/8186http://hdl.handle.net/20.500.12613/8215Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes. Methods: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death. Results: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. Conclusion: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.6 pagesengAttribution-NonCommercial-NoDerivs CC BY-NC-NDhttp://creativecommons.org/licenses/by-nc-nd/4.0/Text